EGFR and non-small cell lung carcinoma: The findings showed that adjuvant therapy with first-generation EGFR-TKIs led to significantly improved 2- and 3-year DFS rates, but there was no significant improvement in the 5-year DFS rate, compared with non-EGFR-TKI treatment for patients with resected EGFR-mutant NSCLC.